Tag: PDAC
-
Immune-Related Genes Shape Pancreatic Cancer Risk and Outcomes, CNIO Study Finds
Overview: Immune Genes and pancreatic cancer In a significant advance for pancreatic cancer research, scientists from the National Cancer Research Centre (CNIO) have identified immune-related genetic variations that affect both the risk of developing pancreatic ductal adenocarcinoma (PDAC) and the outcomes for patients who face this challenging disease. The study adds to the growing body…
-
Immune-Related Genes Shape Pancreatic Cancer Risk and Outcomes Identified
Groundbreaking Discovery in Pancreatic Cancer Genetics Researchers at the National Cancer Research Centre (CNIO) have identified immune-related genetic variants that influence both the risk of developing pancreatic ductal adenocarcinoma (PDAC) and the disease’s survival outcomes after diagnosis. This large-scale genetic analysis highlights how the immune system’s genetic blueprint can shape cancer susceptibility and progression, offering…
-
Immune-Related Genes Shape Pancreatic Cancer Risk and Outcomes
Groundbreaking Findings Link Immune-Related Genes to Pancreatic Cancer Risk A new wave of genetic research from the National Cancer Research Centre (CNIO) is reshaping our understanding of pancreatic ductal adenocarcinoma (PDAC). Scientists have identified specific immune-related gene variations that not only influence a person’s risk of developing PDAC but also shape outcomes after diagnosis. The…
-
Mild Pancreatic Duct Dilatation Linked to Higher Cancer Risk, Johns Hopkins Study Finds
Understanding the Link Between Duct Dilation and Pancreatic Cancer Risk Pancreatic cancer remains one of the deadliest cancers, with rising incidence and late-stage discovery that often limits treatment options. A recent study from Johns Hopkins Medicine sheds light on a potential early warning sign: mild pancreatic duct dilatation. The finding suggests that even subtle changes…
-
Mild Pancreatic Duct Dilatation Signals Higher Cancer Risk, Johns Hopkins Study Finds
New Insights into Pancreatic Cancer Risk Pancreatic cancer remains one of the most deadly cancers, with the National Institutes of Health projecting pancreatic ductal adenocarcinoma to become the second-leading cause of cancer death in the United States by 2030. In this landscape, researchers at Johns Hopkins have explored whether a seemingly small anatomical change—the mild…
-
Pancreatic Cancer Research Project Targets Seeds of Metastasis
New Frontiers in Pancreatic Cancer Research Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest forms of cancer, with a five-year survival rate that has stubbornly lingered in the single digits. A recent research initiative is focusing on a critical phase of disease progression: the early steps that allow pancreatic cancer cells to seed distant…
-
Pancreatic Cancer Research Targets Seeds of Metastasis
New frontiers in the fight against pancreatic cancer Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal forms of cancer, often diagnosed at late stages when treatment options are limited. A leading reason for its grim prognosis is the way PDAC quickly seeds metastasis, spreading to the liver, lungs, and other organs. In a…
-
Stereotactic Body Radiation Therapy in Inoperable PDAC: The TORPEDO Phase II Randomised Trial
Understanding the challenge of inoperable pancreatic cancer Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive solid tumors, with limited treatment options for patients whose disease is non-metastatic but inoperable. For these individuals, conventional treatment often focuses on systemic therapy and palliative care, aiming to control symptoms and extend survival without compromising quality of…
-
Stereotactic Body Radiation Therapy in Inoperable Pancreatic Cancer: Insights from the TORPEDO Phase II Randomised Trial
Overview: The TORPEDO Trial and the Challenge of PDAC Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers, with many patients presenting with tumors that are inoperable or unsuitable for conventional curative surgery. In this context, the TORPEDO trial investigates the potential of stereotactic body radiation therapy (SBRT) as a treatment option to…
-
Stereotactic body radiation therapy and the TORPEDO trial: A new approach for inoperable pancreatic cancer
Overview: SBRT as a potential option for inoperable PDAC Pancreatic ductal adenocarcinoma (PDAC) remains one of the most challenging cancers to treat, especially when surgical options are off the table. For patients with non-metastasized yet inoperable disease, there is a critical need for effective, well-tolerated therapies. The TORPEDO trial investigates stereotactic body radiation therapy (SBRT)…